Also trades as: KSPHF (OTC) · $vol 0M
4547.T JPX
Kissei Pharmaceutical Co., Ltd.
1W: -5.0%
1M: -9.7%
3M: -9.5%
YTD: -20.6%
1Y: -13.8%
3Y: +34.5%
5Y: +90.7%
¥3,700.00 ($23.44)
-130.00 (-3.39%)
Weekly Expected Move ±2.9%
¥3488
¥3594
¥3700
¥3806
¥3912
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Cash Flow Trends
Operating Cash Flow
-$1.5B
-122.8% ▼
Capital Expenditures
$4.9B
-8.3% ▼
5Y CAGR: +26.9%
Free Cash Flow
-$6.4B
-416.2% ▼
Dividends Paid
$4.8B
-27.4% ▼
Buybacks
$5.2B
+1.4% ▲
Net Change in Cash
-$19.1B
-941.1% ▼
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | $16.5B | $13.7B | $11.2B | $12.0B | $13.8B |
| Depreciation & Amort. | $3.7B | $4.1B | $4.3B | $4.8B | $4.6B |
| Stock-Based Comp. | $0 | $0 | $0 | $0 | $0 |
| Change in Working Capital | $116M | -$5.5B | -$9.3B | -$668M | -$1.5B |
| Other Non-Cash Items | -$18.8B | -$19.0B | -$7.8B | -$9.6B | -$18.4B |
| Operating Cash Flow | $1.5B | -$6.7B | -$1.7B | $6.5B | -$1.5B |
| — Investing Activities — | |||||
| Capital Expenditures | -$1.9B | -$2.5B | -$1.2B | -$8.6B | -$5.6B |
| Acquisitions (Net) | -$385M | -$363M | $175M | $519M | $3.4B |
| Investment Purchases | -$5.8B | -$1.9B | -$2.4B | -$978M | -$2.1B |
| Investment Sales | $22.2B | $15.0B | $14.8B | $14.1B | $22.1B |
| Other Investing | -$3.4B | -$4.2B | -$2.7B | -$93M | -$182M |
| Investing Cash Flow | $10.8B | $6.0B | $8.7B | $5.0B | $17.5B |
| — Financing Activities — | |||||
| Net Debt Issuance | -$103M | -$150M | -$150M | -$230M | -$196M |
| Stock Repurchased | $0 | $0 | -$6.0B | -$5.3B | -$5.2B |
| Dividends Paid | -$2.5B | -$3.1B | -$3.7B | -$3.8B | -$4.8B |
| Other Financing | -$117M | -$135M | -$134M | -$1M | -$1M |
| Financing Cash Flow | -$2.8B | -$3.4B | -$10.0B | -$9.3B | -$10.3B |
| Net Change in Cash | $9.6B | -$4.1B | -$3.0B | $2.3B | -$19.1B |
| Cash End of Period | $53.0B | $48.9B | $45.9B | $48.2B | $29.1B |
| Free Cash Flow | -$386M | -$9.2B | -$3.5B | $2.0B | -$6.4B |